NOVA.CN Shariah Compliance
Screening Methodology: AAOIFI
DOUBTFUL
Last Updated: July 18, 2025
Report Source: 2025 1st Quarter Report
Nova Mentis Life Science Corp. Stock Analysis NOVA.CN
Nova Mentis Life Science Corp. is a biotechnology company, which engages in building and supporting a diversified portfolio of cannabis-sector businesses. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-09-22. The firm is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The firm has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The firm operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.
Read More Nova Mentis Life Science Corp (NOVA.CN) Chart
Key Statistics of Nova Mentis Life Science Corp (NOVA.CN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD0.04Volume
15.02KP/E Ratio (TTM)
-52 Week Range
Market Cap
1.27MAvg. Volume
24.08KDividend Yield
-Financial Metrics & Statements of Nova Mentis Life Science Corp (NOVA.CN)
FAQ's for Nova Mentis Life Science Corp (NOVA.CN)
- According to Musaffa’s Shariah screening methodology, Nova Mentis Life Science Corp (NOVA.CN) is currently classified as DOUBTFUL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.